Tesaglitazar

Drug or vehicle was administered prior to the drinking tests as described below. Drugs were administered either intraperitoneally (i.p.; 10mL/kg), subcutaneously (s.c.; 2mL/kg), or per os (p.o.; 5mL/kg; via FTP-20-30 20 gauge, 30 mm length plastic feeding tubes from Instech Laboratories, Inc., Plymouth Meeting, PA, USA). Table S1 specifies doses and routes of administration for each experiment.
Grain ethanol (200 proof, Decon Laboratories, Inc.) was used in all experiments. Drugs administered during ethanol drinking experiments were gabapentin (Sigma-Aldrich, Milwaukee, WI, USA), tesaglitazar (Tocris, Minneapolis, MN, USA), fenofibrate (Sigma-Aldrich, Milwaukee, WI, USA), caffeic acid phenethyl ester (CAPE; Tocris, Minneapolis, MN, USA), ibrutinib (Toronto Research Chemicals, Inc., Toronto, ON, Canda) and rolipram (Sigma-Aldrich, Milwaukee, WI, USA). The vehicle used for gabapentin and CAPE was saline (Baxter Healthcare Corporation, Deerfield, IL, USA), while for tesaglitazar, fenofibrate, and rolipram, the vehicle was saline and 1.5-2% Tween-80 (Sigma-Aldrich, Milwaukee, WI, USA). The vehicle for ibrutinib was saline, 1.75% Tween-80, and 5% DMSO in week 1, and 100% DMSO in week 2. Table S1 provides a list of drugs, doses, and mechanisms of action for each experiment.

Rosiglitazone, pioglitazone, tesaglitazar, GW9662, T0070907, UVI3003 and SR1664 were purchased from Tocris Bioscience (Minneapolis, MN). SR2595 and SR10221 were synthesized according to published methods (25 (link)). GW1929, BADGE (Bisphenol A diglycidyl ether), SR202 and GW6471 were purchased from Sigma-Aldrich (St. Louis, MO).